song zhonghua

song zhonghua


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2019 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
YDYingqi Dai
Yingqi Dai
SZsong zhonghua
song zhonghua
JZJinqing Zhang
Jinqing Zhang
WGWei Gao
Wei Gao
Objectives In this study, we examined available articles from on-line databases to comprehensively investigate the effect of the XPC (xeroderma pigmentosum complementation group C) rs2228000 polymorphism on the risk of different types of clinical cancer. Method We conducted a group of overall and subgroup pooling analyses after retrieving the data from four databases (updated to September 2019). The P value of association, OR (odds ratios) and 95% CI (confidence interval) were calculated. Results We selected a total of 71 eligible studies with 26,835 cancer cases and 37,069 controls from the 1,186 retrieved articles. There is an enhanced susceptibility to bladder cancer cases under T vs. C [P=0.004; OR (95% CI) =1.25 (1.07, 1.45)], TT vs. CC [P=0.001; 1.68 (1.25, 2.26)], CT+TT vs. CC [P=0.016; 1.26 (1.04, 1.53)], and TT vs. CC+ CT [P=0.001; 1.49 (1.18, 1.90)] compared with negative controls. Additionally, there is an increased risk of breast cancer under T vs. C, TT vs. CC and TT vs. CC+ CT (P1). Nevertheless, there is a decreased risk of gastric cancer cases in China under T vs. C [P=0.020; 0.92 (0.85, 0.99)], CT vs. CC [P=0.001, 0.83 (0.73, 0.93)], and CT+TT vs. CC [P=0.003, 0.84 (0.76, 0.94)]. Conclusions The TT genotype of XPC rs2228000 may be linked to an increased risk of bladder and breast cancer, whereas the CT genotype is likely to be associated with reduced susceptibility to gastric cancer in the Chinese population.

1 January 2022 in Stem Cell Research
Verified
Journal Article
Open access
HSHuaqing Sun
Huaqing Sun
QLQian Li
Qian Li
SZsong zhonghua
song zhonghua
LCli chunhua
li chunhua
Lung cancer is the most prevalent and aggressive cancer and is one of the leading causes of cancer-related death worldwide. Hypoxia in the tumor microenvironment is associated with poor patient survival and is a crucial characteristic of solid tumors. A subset of tumor cells, termed cancer stem cells (CSCs), with self-renewal and differentiation capabilities simultaneously, are regarded as responsible for cancer tumorigenesis, resistance to therapeutics, and cancer relapse. Recent advances have revealed that hypoxia plays an essential role in CSCs self-replication maintenance. Yet, the underlying mechanisms of hypoxia that trigger the stemness maintenance of CSCs are still poorly understood. Here, we provide evidence showing that SH2D3A expression level was increased in lung cancer and lung CSCs, and high expression of SH2D3A was associated with the overall survival of patients with lung cancer. Mechanistically, HIF-2α, which is a key transcription factor in response to hypoxia directly binds to the SH2D3A promoter and facilitates SH2D3A expression at the transcription level. SH2D3A was found to be functionally important for lung CSC malignant behaviors such as uncontrolled self-replication and proliferation. We demonstrated that pharmacological downregulation of SH2D3A expression by AM966, a small molecule compound, efficiently induces tumor regression in vitro and in vivo. Thus, this study highlights the biological implications of SH2D3A as a novel prognostic marker and therapeutic target in lung cancer in the future.

24 September 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
WYWei Ye
Wei Ye
SZsong zhonghua
song zhonghua
ZLZhongkun Lin
Zhongkun Lin
Objective. To investigate the effect of camrelizumab + apatinib combined with radiotherapy on the expression of TRIM27, SCC-Ag, and CYFRA21-1 in advanced oligometastatic non-small-cell lung cancer (NSCLC). Methods. A retrospective analysis of patients with oligometastatic NSCLC who were treated at our hospital from January 1, 2021, to March 31, 2022. Patients who met the inclusion criteria were summarized into an observation group (camrelizumab on the basis of the control group), or a control group (radiotherapy combined with oral apatinib). The disease control rate, immune function, changes in the levels of TRIM27, SCC-Ag, CYFRA21-1, and the occurrence of adverse effects were compared between the two groups. Result. There were 86 patients who met the inclusion criteria, with 53 cases in the observation group and 33 cases in the control group. There were significant differences in complete remission (CR, 25/53 vs. 10/33), partial remission (PR, 17/53 vs. 12/33), disease control (DC, 7/53 vs. 4/33), disease progression (DP, 4/53 vs. 7/33), and disease control rate (49/53 vs. 26/33) between the observation group and the control group. There was no significant difference in immune function between the two groups before treatment ( ). After treatment, the levels of CD3+, CD4+, CD4+/CD8+t cells, and NK cells in the observation group were higher ( , 0.035, 0.003, 0.001, respectively), while the level of CD8+t cells was lower ( ). There were no significant differences in TRIM27, SCC-Ag, or CYFRA21-1 between the two groups before treatment ( ). After treatment, the observation group had lower levels of TRIM27 ( ), SCC-Ag ( ), and CYFRA21-1 ( ). There was no significant difference in the occurrence of adverse events between the two groups ( ). Conclusion. Treatment of camrelizumab + apatinib combined with radiotherapy is effective for advanced oligometastatic NSCLC, with mild adverse effects.